Geron (GERN) Stock: Buy, Sell, or Hold?
GERN - Geron Corp
$1.13
-0.03 (-2.59%)
▼
5d:
-8.13%
30d:
-8.87%
90d:
-20.42%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 04, 2026
11d
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GERN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GERN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.13, which is considered oversold relative to its 30-day fair value range of $1.19 to $1.29. From a valuation perspective, the stock is trading at a premium (Forward PE: 28.2) compared to its historical average (25.1). At these levels, the market is pricing in 4.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a downtrend. The price is currently testing key support at $1.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.25 (+276.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GERN is in a downtrend. The price is currently testing key support at $1.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.25 (+276.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.19 -
$1.29
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.5%
Protect Your Profits
Holding GERN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (52/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 276.1% below Wall St target ($4.25)
- NEUTRAL: Market pricing in 4.0% annual earnings growth - fairly valued
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.19 -
$1.29
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.12
Resistance Level
$1.26
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.25
Wall Street Target
$4.25
(+276.1%)
Revenue Growth (YoY)
17.2%
Profit Margin
-33.1%
Valuation Premium vs History
+4.0% premium
PE vs Historical
28.3 vs 25.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.0%
(market-implied from PE analysis)
1-Year Target
$1.18
(+4%)
2-Year Target
$1.22
(+8%)
3-Year Target
$1.27
(+13%)
3-Yr Target (if PE normalizes)
(PE: 28→25)
PE COMPRESSION
$1.13
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 22, 2026 11:23 PM ET
Data refreshes hourly during market hours. Next update: 12:23 AM
Data refreshes hourly during market hours. Next update: 12:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 62 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 44 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 66 BUY |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
